GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » EV-to-Revenue

Ono Pharmaceutical Co (Ono Pharmaceutical Co) EV-to-Revenue : 1.66 (As of May. 16, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ono Pharmaceutical Co's enterprise value is $5,746 Mil. Ono Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $3,451 Mil. Therefore, Ono Pharmaceutical Co's EV-to-Revenue for today is 1.66.

The historical rank and industry rank for Ono Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

OPHLY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.73   Med: 4.58   Max: 16.7
Current: 1.66

During the past 13 years, the highest EV-to-Revenue of Ono Pharmaceutical Co was 16.70. The lowest was 1.73. And the median was 4.58.

OPHLY's EV-to-Revenue is ranked better than
61.6% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.395 vs OPHLY: 1.66

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-16), Ono Pharmaceutical Co's stock price is $4.94. Ono Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $2.39. Therefore, Ono Pharmaceutical Co's PS Ratio for today is 2.06.


Ono Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Ono Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co EV-to-Revenue Chart

Ono Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.95 4.37 3.86 2.68 1.91

Ono Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 2.52 2.56 2.16 1.91

Competitive Comparison of Ono Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ono Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's EV-to-Revenue falls into.



Ono Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Ono Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5745.605/3451.015
=1.66

Ono Pharmaceutical Co's current Enterprise Value is $5,746 Mil.
Ono Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,451 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ono Pharmaceutical Co  (OTCPK:OPHLY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Ono Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.94/2.394
=2.06

Ono Pharmaceutical Co's share price for today is $4.94.
Ono Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ono Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines